Primary drug treatment for glaucoma: beta-blockers versus other medications.
Stamper Robert L, Wigginton Stephen A, Higginbotham Eve J
AI Summary
This review discussed primary glaucoma drug treatment, concluding individualized patient needs, efficacy, compliance, cost, and side effects dictate the best choice, not a single superior class.
Abstract
This set of Viewpoints articles examines the merits of beta-blockers versus other medications as the primary drug treatment for glaucoma. Ophthalmologists must balance issues such as efficacy, compliance, cost, and side effects when deciding on the appropriate medication to prescribe. Dr. Stamper stresses the advantages of tailoring the choice of medication to the needs of the individual patient. Drs. Wigginton and Higginbotham review the benefits of beta-blockers and present some of the disadvantages of the non-beta-blocker class of medications.
MeSH Terms
Shields Classification
Related Articles5
Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3).
Randomized Controlled TrialPartial Stenosis and Complete Punctal Closure Following Topical Netarsudil Use for Glaucoma.
Case SeriesComparative efficacy and safety of preserved versus preservative-free beta-blockers in patients with glaucoma or ocular hypertension: a systematic review.
Systematic ReviewClinical Dilemma-Topical Prostaglandin Use in Glaucoma During Pregnancy.
Case ReportNew glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
ReviewIs this article assigned to the wrong chapter(s)? Let us know.